PMLiVE1d
CHMP recommends Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years
The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...
Hosted on MSN3d
Replicate’s rabies vaccine rivals Bavarian Nordic’s RavAlert at Phase I
The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...